Ethanol Inhibition
of Porcine Bioprosthetic Heart Valve Cusp Calcification Is Enhanced by
Reduction with Sodium Borohydride
Jeanne M. Connolly, Ivan Alferiev, Allyson Kronsteiner, Zhibin Lu,
Robert J. Levy
Cardiology Research Laboratory, The Children’s
Hospital of Philadelphia, Philadelphia, PA, USA |
Background and aim of the study: Previous studies
have shown that ethanol pretreatment of glutaraldehyde (GA)-fixed porcine
aortic valve cusps (GPAV) significantly reduces bioprosthetic leaflet
calcification. The anticalcification mechanism is due to extraction of
cholesterol and phospholipids, and a permanent alteration in collagen
structure. It was noted in experimental implants that ethanol-pretreated
GPAV occasionally show low levels of calcification. The study aim was
to investigate whether this was due to unreacted aldehyde residues and
other reducible compounds resulting from GA cross-linking.
Methods: GPAV were cross-linked in GA (0.6%) and stored
at pH 7.4 in 0.2% GA. Cusps were pretreated with ethanol (80%,
pH 7.4) for 24 h. Experimental groups included ethanol-pretreated
cusps and GA-fixed controls that were pretreated with either sodium
borohydride or sodium cyanoborohydride. Differential scanning calorimetry
was used to measure shrink temperature as a measure of cross-linking.
Subdermal implants of valve cusp tissue were carried out in 21-day-old
Sprague-Dawley male rats. Implants were retrieved at 21 days |
and samples assessed for the extent of calcification using
chemical analyses for Ca, and microscopy studies.
Results: Ethanol pretreatment significantly inhibited
calcification compared with controls (13.3 ± 5.6 versus
119.2 ± 6.6 mg Ca/mg tissue; p <0.001). However, sodium
borohydride reduction under optimized conditions combined with
ethanol pretreatment optimally reduced calcification (1.16 ± 0.1
mg Ca/mg; p <0.05), whereas levels after sodium cyanoborohydride
treatment (23.6 ± 10.4 mg Ca/mg) were not significantly
different to those after ethanol alone. Neither reducing agent
was effective in inhibiting calcification without ethanol pretreatment.
Furthermore, the reducing agents had no significant effect on shrink
temperature.
Conclusion: Inhibition of GPAV calcification with ethanol
pretreatment can be enhanced through the optimized use of reducing
agents. This indicates that reducible aldehyde-related moieties
are likely responsible for breakthrough calcification, even after
ethanol pretreatment.
The Journal of Heart Valve Disease 2004;13:487-493 |